![Insights from 2023 ASCO® Annual Meeting](http://media.vumedi.com/thumbs/channel_logo/2023/5/a2df459d-f523-49c6-86db-fbc880f4b695.png.200x0_q85.png)
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Biomarker Analysis of 2 Zolbetuximab Phase 3 Studies (SPOTLIGHT & GLOW) - Global Prevalence of CLDN18.2 in Locally Advanced Unresectable/Metastatic Gastric/GEJ Adenocarcinoma"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Kohei Shitara
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Kohei Shitara
511 views
June 12, 2023
Comments 0
Login to view comments.
Click here to Login
GI